GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.38 (+0.35%)

Growth Price

Overvalued by 10.21%

Stability Price

Overvalued by 64.39%

Company Metrics

  • P/E 9.93
  • P/S 4.94
  • P/B 8.97
  • EPS 10.89
  • Cash ROIC 43.15%
  • Cash Ratio 1.76
  • Dividend 1.72 / 1.61 %
  • Avg. Vol. 11.07M
  • Shares 1.65B
  • Market Cap. 155.88B

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Gilead Sciences Stock Forecast For 2016
Seeking Alpha - Nov 26, 2015
Gilead Sciences (NASDAQ:GILD) debuted on the Nasdaq in the early months of 1992. The initial IPO raised $86.25 million in proceeds.
Gilead Sciences Inc. (NASDAQ:GILD) – Large Cap Morning Report - Wall Street Observer
Gilead Sciences Inc (GILD) Files Form 4 Insider Selling : John Francis Cogan ... - Insider Trading Report
Gilead Sciences Inc. Has Plenty of Room to Run in Hepatitis C
Motley Fool - Nov 21, 2015
Gilead Sciences (NASDAQ:GILD) has had a massively successful run with its hepatitis C cures Sovaldi and Harvoni, and the more I look at the market size and the company's treatment strategy, the more I become convinced this business has plenty of room ...
Gilead Sciences: New Script Data Add To A Great Month For HCV - Bidness ETC
Better Dividend Stock: Gilead Sciences Inc. vs. Teva Pharmaceutical Industries
Motley Fool - Nov 16, 2015
Gilead Sciences (NASDAQ:GILD), for example, is one of the relatively few biotechs that pays a dividend. Meanwhile, Teva Pharmaceutical Industries (NYSE:TEVA) stands out with one of the best dividend yields among generic-drug makers.
Biotech Stocks to Love: Macrocure Ltd (NASDAQ:MCUR), Gilead Sciences, Inc ...
Wall Street Point - Nov 26, 2015
Gilead Sciences, Inc. (NASDAQ:GILD) closed at $107.78 with an increase of 1.14%. The $155.33B company on November 24, 2015 announced webcasts from two upcoming investor conferences: the 33rd NASDAQ OMX Investor Program in London and the ...
Gilead Sciences, Inc. (GILD): Options Market Mispricing Risk
Smarter Analyst - Nov 12, 2015
The options market appears to be underestimating the risk to Gilead Sciences, Inc. (NASDAQ:GILD)'s share price ahead of an event that could intensify the bear's thesis concerning GILD's sustainability problems due to competitive threats from MRK and ...
Updating My Price Target On Gilead Sciences - Seeking Alpha
John Milligan Insider Selling for 100000 Shares of Gilead Sciences, Inc ... -
Price Target Update on Gilead Sciences, Inc. (NASDAQ:GILD)
Money Flow Index - Nov 19, 2015
Gilead Sciences, Inc. (NASDAQ:GILD): The mean short term price target for Gilead Sciences, Inc. (NASDAQ:GILD) has been established at $126 per share.
Here is What Hedge Funds Think About Gilead Sciences, Inc. (GILD) - Insider Monkey (blog)
Needham Shines Light on Gilead Sciences, Inc. (GILD) and Regulus Therapeutics ...
Smarter Analyst - Nov 20, 2015
Needham's healthcare analyst Alan Carr weighted in today on the pharmaceutical giant Gilead Sciences, Inc. (NASDAQ:GILD) and San Diego biopharmaceutical company Regulus Therapeutics Inc (NASDAQ:RGLS), after hosting a call yesterday with KOL ...
Gilead Sciences Lowered to "Buy" at Vetr Inc. (GILD)
Dakota Financial News - 10 hours ago
Gilead Sciences logo Gilead Sciences (NASDAQ:GILD) was downgraded by stock analysts at Vetr from a “strong-buy” rating to a “buy” rating in a research note issued on Thursday, MarketBeat Ratings reports.
Gilead Sciences Lowered to “Buy” at Vetr Inc. (GILD) - WKRB News
Active Biotech Stock News: Gilead Sciences, Inc. (GILD), Biogen Inc (BIIB ... - Investor Wired
Gilead Sciences: HCV And HIV Revenue Stream Not About To Dry Up
Bidness ETC - Nov 23, 2015
Gilead Sciences Inc. (NASDAQ:GILD) is still leading the HCV and HIV race despite tough competition from formidable rivals as well as new entrants in the space.
Another Strong Quarter for Gilead Sciences, Inc.
Motley Fool - Oct 29, 2015
Gilead Sciences (NASDAQ:GILD) exceeded expectations when it reported financial results three months ago. Some big questions loomed large, though, as the biotech wrapped up its third quarter.
Gilead Sciences, Inc. - GILD Stock Catches the Bears Off Guard Again -
Needham Bullish on Two Biotech Giants: Gilead Sciences, Inc. (GILD) and ... - Smarter Analyst